Tag Mass.

Momenta Pharmaceuticals Obtains Temporary Restraining Order Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd.

Oct7

CAMBRIDGE, Mass., Oct. 7, 2011 (GLOBE NEWSWIRE) Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the United States District Court for the District of Massachusetts today entered an order enjoining Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. from offering to […]

pSivida Announces Opening of Investigator-Sponsored Trial for Injectable, Sustained Release FAc Insert for Posterior Uveitis

Sep12

WATERTOWN, Mass.(BUSINESS WIRE) Drug delivery company pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) today announced the opening of an investigational new drug application (IND) for a Phase I/II clinical trial to study pSivida’s injectable, sustained release insert delivering the corticosteroid fluocinolone acetonide (FAc) for the treatment of uveitis affecting the posterior segment of the eye (posterior uveitis). An […]

Millennium Pharmaceutical Becomes First Licensed Customer for BioClinica’s New Enterprise Demand Aggregator

Mar29

Will Provide Enterprise-Wide Control for Clinical Supply Planning and Manufacturing NEWTOWN, Pa.(BUSINESS WIRE) BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, has signed a technology agreement with Millennium: The Takeda Oncology Company, (Millennium) a leading biopharmaceutical company. This agreement makes Millennium the first customer for BioClinica’s new Enterprise Demand Aggregator (EDA?) […]

Pathfinder Cells Demonstrate Ability to Regenerate Damaged Tissue and Restore Pancreatic Function in a Diabetic Mouse Model

Mar28

CAMBRIDGE, Mass., March 29, 2011 /PRNewswire/ Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage ("Pathfinder"), today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model. The results of the study, which will […]

Cambridge Heart’s MTWA Test Featured as Case of the Week in Diagnostic and Interventional Cardiology

Mar27

TEWKSBURY, Mass.(BUSINESS WIRE) Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that its Microvolt T-Wave Alternans (MTWA) test was recently featured in Diagnostic and Interventional Cardiology (DAIC) as the Case of the Week. The clinical case illustrates the prognostic value of the test in a patient who […]

Leading Cardiology Practices Adopt lifeIMAGE to Instantly and Securely Exchange Patient Imaging and Records

Mar27

Boston, MA (PRWEB) March 28, 2011lifeIMAGE announced today that the pediatric cardiology group at Montefiore Medical Center (Bronx, N.Y.) and the heart and vascular program at Baystate Health System (Springfield, Mass.) are using the lifeIMAGE network to share patients cardiac and echocardiography imaging records. lifeIMAGE, which enables the secure and on-demand exchange of medical imaging […]

Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System

Mar23

NATICK, Mass., March 24, 2011 /PRNewswire/ Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Clik? Anchor for its Precision Plus? Spinal Cord Stimulator (SCS) System, the world's first rechargeable SCS device for chronic pain management. The Clik Anchor features an innovative locking system designed […]

BG Medicine Announces Availability of Galectin-3 Testing Service Through Health Diagnostic Laboratory, Inc.

Mar23

WALTHAM, Mass. and RICHMOND, Va., March 24, 2011 (GLOBE NEWSWIRE) BG Medicine, Inc. (Nasdaq:BGMD) and Health Diagnostic Laboratory, Inc. (HDL, Inc.), announced today an agreement under which HDL, Inc. will offer galectin-3 testing services based on the BG Medicine Galectin-3 Test. The BG Medicine Galectin-3 Test was recently cleared by the FDA as an aid […]

Abiomed to Host PROTECT II Investor Meeting at ACC 2011

Mar23

- Presentation Will Be Webcast Live and Available on Abiomed Website DANVERS, Mass.(BUSINESS WIRE) Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, will host a PROTECT II investor and analyst meeting and webcast from ACC 2011 on Monday, April 4, from 8:00 9:00 a.m. ET. The presentation will include the PROTECT […]

FDA clears anchor for Boston Science device

Mar23

NATICK, Mass. Boston Scientific Corp. said Thursday that regulators approved marketing of an anchor for its Precision Plus Spinal Cord Stimulator System, a device that treats trunk and limb pain with electrical stimulation.The company said the Food and Drug Administration cleared its New Clik Anchor. The anchor is designed to hold the wires of the […]